FMI Foundation Medicine Inc.

Foundation Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine today announced that Troy Cox, chief executive officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 3:30 p.m. PST in San Francisco. Additionally, Troy Cox will participate in a panel discussion focused on the Food & Drug Administration and Centers for Medicare and Medicaid Services Parallel Review process on Monday, January 8, 2018 at 5:15 p.m. PST.

Live, listen-only webcasts of these presentations can be accessed by visiting the investors section of the Foundation Medicine website at investors.foundationmedicine.com. A replay of the webcasts will be available shortly after the conclusion of the presentation and archived on the company's website for two weeks following the presentations.

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

EN
03/01/2018

Underlying

FMIFoundation Medicine Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Foundation Medicine Inc.

Free Trial
FMI Foundation Medi...

1 director sold

A director at Foundation Medicine Inc sold 73,173 shares at 137.000USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

FMI FOUNDATION MEDICINE INC.
08/03/18 August 3, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine Announces 2018 First Quarter Results and Recent Hi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the first quarter ended March 31, 2018. Highlights for the quarter included: Posted revenue of $52.8 million, 101% year-over-year growth; Reported 21,861 clinical tests, 57% year-over-year growth; Achieved broad Medicare coverage through a final National Coverage Determination (NCD) from the Centers for Medicare and Medicaid Services (CMS) for FoundationOne...

May 2, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine Launches Gene Expression Profiling Program to Iden...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development. This initiative, which provides a natural complement to Foundation Medicine’s comprehensive genomic profiling (CGP) suite of molecular information tests, further enhances support for the Company’s biopharma partners in the efficient identification of known and novel genomic and expression-based biomarkers of response fo...

May 2, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., (NASDAQ:FMI), F. Hoffmann-La Roche Ltd (Roche) and DIAN Diagnostics Group, Co., Ltd. (DIAN), today announced a three-party collaboration to integrate Foundation Medicine’s comprehensive genomic profiling (CGP) assays into clinical patient care in mainland China. Under the collaboration: DIAN, a leader in the development and supply of Chinese medical diagnostic products and services, becomes the exclusive clinical sequencing partner in China for...

April 26, 2018 1 EN
 PRESS RELEASE
Free
FMI Foundation Medi...

Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough D...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for its new liquid biopsy assay, which is an expanded version of its FoundationACT® assay. The new assay will include more than 70 genes and genomic biomarkers for microsatellite instability (MSI) and blood tumor mutational burden (bTMB). If approved, this test could be the first FDA-approved liquid biopsy...

April 26, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch